Evaluation and metabolite studies of 125I- and 123I-labelled E-(R,R)-IQNP:: Potential radioligands for visualization of M1 muscarinic acetylcholine receptors in brain

被引:6
作者
Bergstrom, KA [1 ]
Halldin, C
Hiltunen, J
Swahn, CG
Ito, H
Ginovart, N
Hall, H
McPherson, DW
Knapp, FFR
Larsson, S
Schnell, PO
Farde, L
机构
[1] Kuopio Univ Hosp, Dept Clin Physiol, FIN-70210 Kuopio, Finland
[2] Karolinska Hosp & Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden
[3] Karolinska Hosp & Inst, Dept Clin Neurosci, Nucl Med Sect, S-17176 Stockholm, Sweden
[4] Map Med Technol, FIN-41160 Tikkakoski, Finland
[5] Oak Ridge Natl Lab, Nucl Med Grp, Oak Ridge, TN 37831 USA
关键词
E-(R; R)-IQNP; muscarinic acetylcholine receptors; brain; SPET; autoradiography;
D O I
10.1016/S0969-8051(97)00198-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A new ligand for the M-1 muscarinic receptor subtype, E-(R,R)-1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate (E-IQNP), was labelled with I-125 and I-123 for autoradiographic studies on human whole-brain cryosections and SPET studies, respectively, in Cynomolgus monkey. Autoradiography demonstrated E-[I-125]IQNP binding in M-1 receptor-rich regions such as the neocortex and the striatum. The binding was displaceable by the selective M-1 antagonist biperiden. In vivo single photon emission tomography (SPET) studies with E-[I-123]IQNP demonstrated a high accumulation of radioactivity in the monkey neocortex, Rapid hydrolysis of the quinuclidinyl ester to the free acid was found to be a major biotransformation route for E-[I-123]IQNP. The free acid of E-[I-123]IQNP does not pass the blood-brain barrier, but the plasma concentration was high as compared to the total radioactivity in brain. It is thus necessary to correct for the high concentration of radioactive metabolites in parenchymal blood (CBV) to obtain accurate values for E-[I-123]IQNP binding in brain. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 24 条
[1]  
[Anonymous], 1995, DEV NUCL MED
[2]  
Bergstrom K A, 1994, J Nucl Biol Med, V38, P128
[3]  
BERGSTROM KA, 1997, P 12 INT S RAD CHEM, P154
[4]  
BERGSTROM KA, 1996, PSYCHOPHARMACOLOGIA, V11, P483
[5]   EXTERNAL IMAGING OF CEREBRAL MUSCARINIC ACETYLCHOLINE-RECEPTORS [J].
ECKELMAN, WC ;
REBA, RC ;
RZESOTARSKI, WJ ;
GIBSON, RE ;
HILL, T ;
HOLMAN, BL ;
BUDINGER, T ;
CONKLIN, JJ ;
ENG, R ;
GRISSOM, MP .
SCIENCE, 1984, 223 (4633) :291-293
[6]   MUSCARINIC RECEPTORS AND NOVEL STRATEGIES FOR THE TREATMENT OF AGE-RELATED BRAIN DISORDERS [J].
EHLERT, FJ ;
ROESKE, WR ;
YAMAMURA, HI .
LIFE SCIENCES, 1994, 55 (25-26) :2135-2145
[7]   AFFINITY AND SELECTIVITY OF BIPERIDEN ENANTIOMERS FOR MUSCARINIC RECEPTOR SUBTYPES [J].
ELTZE, M ;
FIGALA, V .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 158 (1-2) :11-19
[8]  
Hall H, 1996, SYNAPSE, V23, P115, DOI 10.1002/(SICI)1098-2396(199606)23:2<115::AID-SYN7>3.0.CO
[9]  
2-C
[10]   DISTRIBUTION OF D-1-DOPAMINE AND D-2-DOPAMINE RECEPTORS, AND DOPAMINE AND ITS METABOLITES IN THE HUMAN BRAIN [J].
HALL, H ;
SEDVALL, G ;
MAGNUSSON, O ;
KOPP, J ;
HALLDIN, C ;
FARDE, L .
NEUROPSYCHOPHARMACOLOGY, 1994, 11 (04) :245-256